Serum apolipoprotein A-I concentration differs in coronary and peripheral artery disease

References

• Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116(9):1509–1526.
   PubMed Web of Science ®Google Scholar
• Aboyans V, Ricco J-B, Bartelink MEL, et al. Editor’s choice - 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc J. 2018;55:305–368.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285(19):2481–2485.
   PubMed Web of Science ®Google Scholar
• Tunstall-Pedoe H, Peters SAE, Woodward M, et al. Twenty-year predictors of peripheral arterial disease compared with coronary heart disease in the Scottish heart health extended cohort (SHHEC). J Am Heart Assoc. 2017;6:e005967.
   PubMed Web of Science ®Google Scholar
• Keil U. Coronary artery disease: the role of lipids, hypertension and smoking. Basic Res Cardiol. 2000;95(Suppl 1):I52–I58.
   PubMedGoogle Scholar
• Mach F, Baigent C, Catapano AL, et al. ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205.
   PubMed Web of Science ®Google Scholar
• Morris PB, Ballantyne CM, Birtcher KK, et al. Review of clinical practice guidelines for the management of LDL-related risk. J Am Coll Cardiol. 2014;64(2):196–206.
   PubMed Web of Science ®Google Scholar
• Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337–345.
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I, Aastveit AH, et al. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med. 2004;42(12):1355–1363.
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358(9298):2026–2033.
   PubMed Web of Science ®Google Scholar
• Laschkolnig A, Kollerits B, Lamina C, et al. Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res. 2014;103(1):28–36.
   PubMed Web of Science ®Google Scholar
• Aboyans V, Criqui MH, Denenberg JO, et al. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation. 2006;113(22):2623–2629.
   PubMed Web of Science ®Google Scholar
• Niemi J, Mäkinen VP, Heikkonen J, et al. Estimation of VLDL, IDL, LDL, HDL2, apoA-I, and apoB from the Friedewald inputs-apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes. Ann Med. 2009;41(6):451–461.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
   PubMed Web of Science ®Google Scholar
• Dalén M, Lund LH, Ivert T, et al. Survival after coronary artery bypass grafting in patients with preoperative heart failure and preserved vs reduced ejection fraction. JAMA Cardiol. 2016;1(5):530–538.
   PubMed Web of Science ®Google Scholar
• Thorsteinsson K, Fonager K, Mérie C, et al. Age-dependent trends in postoperative mortality and preoperative comorbidity in isolated coronary artery bypass surgery: a nationwide study. Eur J Cardiothorac Surg. 2016;49(2):391–397.
   PubMed Web of Science ®Google Scholar
• Soden PA, Zettervall SL, Shean KE, et al. Regional variation in outcomes for lower extremity vascular disease in the Vascular Quality Initiative. J Vasc Surg. 2017;66(3):810–818.
   PubMed Web of Science ®Google Scholar
• Jang SY, Ju EY, Cho SI, et al. Comparison of cardiovascular risk factors for peripheral artery disease and coronary artery disease in the Korean population. Korean Circ J. 2013;43(5):316–328.
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Housley E, Riemersma RA, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol. 1992;135(4):331–340.
   PubMed Web of Science ®Google Scholar
• Price JF, Mowbray PI, Lee AJ, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J. 1999;20(5):344–353.
   PubMed Web of Science ®Google Scholar
• Jousilahti P, Vartiainen E, Tuomilehto J, et al. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation. 1999;99(9):1165–1172.
   PubMed Web of Science ®Google Scholar
• Chen DC, Armstrong EJ, Singh GD, et al. Adherence to guideline-recommended therapies among patients with diverse manifestations of vascular disease. Vasc Health Risk Manag. 2015;11:185–192.
   PubMed Web of Science ®Google Scholar
• DeCarlo C, Scher L, Shariff S, et al. Statin use and other factors associated with mortality after major lower extremity amputation. J Vasc Surg. 2017;66(1):216–225.
   PubMed Web of Science ®Google Scholar
• Kulik A, Shrank WH, Levin R, et al. Adherence to statin therapy in elderly patients after hospitalization for coronary revascularization. Am J Cardiol. 2011;107(10):1409–1414.
   PubMed Web of Science ®Google Scholar
• O'Donnell TFX, Deery SE, Darling JD, et al. Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. J Vasc Surg. 2017;66(2):572–578.
   PubMed Web of Science ®Google Scholar
• Stavroulakis K, Borowski M, Torsello G, et al. Association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registry. J Vasc Surg. 2017;66(5):1534–1542.
   PubMed Web of Science ®Google Scholar
• McTaggart F, Jones P. Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther. 2008;22(4):321–338.
   PubMed Web of Science ®Google Scholar
• Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation. 1997;96(1):37–43.
   PubMed Web of Science ®Google Scholar
• Lu M, Lu Q, Zhang Y, et al. ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity. J Biomed Res. 2011;25(4):266–273.
   PubMedGoogle Scholar
• Oksala N, Seppälä I, Hernesniemi J, et al. Complementary prediction of cardiovascular events by estimated apo- and lipoprotein concentrations in the working age population. The Health 2000 Study. Ann Med. 2013;45(2):141–148.
   PubMed Web of Science ®Google Scholar
• van Capelleveen JC, Bochem AE, Boekholdt SM, et al. Association of high-density lipoprotein-cholesterol versus apolipoprotein A-I with risk of coronary heart disease: the European Prospective Investigation into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women’s Health Study. J Am Heart Assoc. 2017;6:e006636.
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Arsenault BJ, Hovingh GK, et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation. 2013;128(14):1504–1512.
   PubMed Web of Science ®Google Scholar
• Pol T, Held C, Westerbergh J, et al. Dyslipidemia and risk of cardiovascular events in patients with atrial fibrillation treated with oral anticoagulation therapy: insights from the ARISTOTLE (Apizaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. J Am Heart Assoc. 2018;7:e007444.
   PubMed Web of Science ®Google Scholar
• Ahnström J, Gottsäter A, Lindblad B, et al. Plasma concentrations of apolipoproteins A-I, B, and M in patients with critical limb ischemia. Clin Biochem. 2010;43(6):599–603.
   PubMed Web of Science ®Google Scholar
• Skinner JS, Farrer M, Albers CJ, et al. High apolipoprotein AI concentrations are associated with lower mortality and myocardial infarction five years after coronary artery bypass graft surgery. Heart. 1999;81(5):488–494.
   PubMed Web of Science ®Google Scholar